Feasibility study of hyperthermic treatment by ASKIRF-8 for solid tumors
Phase 2
Recruiting
- Conditions
- Solid tumors
- Registration Number
- JPRN-UMIN000048984
- Lead Sponsor
- Matsunami General Hospital Division of Hematology and Medical Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.Ophthalmological cancer and brain tumors 2.Hematological malignancies 3.Metal in around the treatment region
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Completion rate of scheduled hyperthermic treatment
- Secondary Outcome Measures
Name Time Method Incidence and grade of adverse reactions. 6-month and 1-year overall survival 6-month and 1-year relapse free survival